HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Chris Roberts as vice president of medical innovation. Roberts joins HTG from Caris Life Sciences where he served as vice president of the oncology division and helped build the Caris Target NowTM business line into a global leader of molecular profiling services. Roberts also served as a director in the molecular diagnostic and strategic marketing divisions at Ventana Medical Systems, a member of the Roche group. He earned a B.S. in chemical engineering from Georgia Tech and an MBA from Duke University. Read more »

Sam Rua, vice president of regulatory affairs and quality systems at HTG Molecular Diagnostics, will offer a keynote presentation, “Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests,” at the 2012 TIDES Oligonucleotide and Peptide Research, Technology and Development conference in Las Vegas on Tuesday, May 22. Read more »

HTG Molecular Diagnostics has established a collaborative program with Sanofi US to identify biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent. HTG Molecular Diagnostics’ qNPA technology measures mRNA and/or miRNA expression in formalin fixed paraffin embedded (FFPE) tumor samples, allowing clinicians to verify the presence of certain biomarkers relevant to patient selection and therapy. Read more »

HTG Molecular, a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans, Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holzer, Ph.D., M.A., Vice President of Clinical Diagnostic Development; and Sam Rua, Vice President of Regulatory Affairs and Quality Systems. Read more »